Skip to content
ATLAS PREP HQ
Growth Hormone

CJC-1295 NO DAC + Ipamorelin

Modified GRF(1–29) / CJC-1295 no-DAC plus ipamorelin

GHRH plus growth-hormone secretagogue research intended to support more pulsatile GH release.

Limited Human Evidence

Route

Subcutaneous.

Common format

5 mg + 5 mg

Research focus

pulsatile GH release

Evidence level

Limited Human Evidence

Typical cycle

8–12 weeks

Growth Hormone research motifGrowth Hormone

CJC-1295 NO DAC + Ipamorelin in 30 seconds

Atlas Fast Read

What it is

Modified GRF(1–29) / CJC-1295 no-DAC plus ipamorelin

Why people care

GHRH plus growth-hormone secretagogue research intended to support more pulsatile GH release.

Human evidence

Limited Human Evidence — Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.

Biggest misconception

Key gaps include larger independent trials, clearer dose-response data, long-term safety, clinically meaningful endpoints, and evidence that findings generalize beyond the narrow populations or routes already studied.

Bottom line

CJC-1295 NO DAC + Ipamorelin has a real human signal or documented human pharmacology, but evidence is too small, mixed, route-specific, or indication-specific to justify broad claims.

Overview

What is CJC-1295 NO DAC + Ipamorelin?

CJC-1295 NO DAC + Ipamorelin is modified GRF(1–29) / CJC-1295 no-DAC plus ipamorelin. GHRH plus growth-hormone secretagogue research intended to support more pulsatile GH release.

This combination arose from growth-hormone-secretagogue practice rather than a single approved drug program. Modified GRF provides GHRH-receptor stimulation while ipamorelin activates the ghrelin/GHS receptor.

Mechanism

How it works

Modified GRF stimulates the GHRH receptor while ipamorelin stimulates GHSR-1a. Simultaneous signaling can amplify a physiologic GH pulse more than either pathway alone while preserving endogenous feedback.

Research areas

pulsatile GH releaseIGF-1recoverybody composition

Evidence

What does the evidence actually say?

Limited Human Evidence

Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

Human evidence for the exact combination is limited. Each pathway has human endocrine pharmacology data, but controlled trials showing meaningful body-composition, recovery, or longevity benefits from the paired protocol are lacking.

Preclinical evidence

Preclinical endocrine work supports synergistic signaling between GHRH-receptor agonism and ghrelin-receptor agonism. Evidence for downstream recovery/body-composition outcomes is far weaker.

Knowledge gaps

Key gaps include larger independent trials, clearer dose-response data, long-term safety, clinically meaningful endpoints, and evidence that findings generalize beyond the narrow populations or routes already studied.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

Community reference: 100–300 mcg of each peptide once daily with gradual titration.

Frequency

Once daily in the community sources blend protocol.

Timing

Commonly before bed or on waking, often separated from large meals in community practice; exact timing has not been clinically validated for performance outcomes.

Route

Subcutaneous.

Cycle length

8–12 weeks

Reconstitution

Community reference: 2 mL bacteriostatic water per 10 mg blend = 5 mg/mL total, 2.5 mg/mL of each peptide.

Storage

Community reference: lyophilized frozen; reconstituted 2–8 °C; avoid repeated freeze-thaw.

Monitoring

IGF-1, fasting glucose/HbA1c, edema, BP, sleep and symptoms of excessive GH effect. Consider cortisol/prolactin only when clinically indicated.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Potential GH/IGF-axis effects include edema, joint pain, tingling/carpal-tunnel-like symptoms, headache, flushing, increased appetite in some secretagogues, and worsening glucose tolerance. Injection-site reactions can occur.

Contraindications

Avoid in active malignancy and use extreme caution with uncontrolled diabetes, proliferative retinopathy, untreated pituitary disease, pregnancy/breastfeeding or significant edema. Exact contraindications are not established for research formulations.

Interactions

GH/IGF signaling can alter glucose control, so insulin and other glucose-lowering therapy may require closer monitoring. Glucocorticoids can blunt GH effects; thyroid status can influence response. Formal interaction data are limited for research secretagogues.

Stacks

Common stacks

CJC-1295 no-DAC + Ipamorelin

The entry is itself a dual secretagogue protocol: GHRH-receptor plus GHSR signaling.

Human endocrine rationale exists; downstream performance/recovery outcomes remain limited.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

CJC-1295 NO DAC + Ipamorelin has a real human signal or documented human pharmacology, but evidence is too small, mixed, route-specific, or indication-specific to justify broad claims. The most defensible use of the literature is to separate what has actually been measured in people from what is still extrapolated from mechanism or animal work.

More in Growth Hormone

Growth Hormone

CJC-1295 DAC

Long-acting GHRH analog research designed to extend growth-hormone signaling over multiple days.

Read guide

Growth Hormone

GHRP-2

Ghrelin-receptor agonist research focused on stimulating growth-hormone secretion.

Read guide

Growth Hormone

GHRP-6

Ghrelin-mimetic peptide research examining growth-hormone release and ghrelin-receptor signaling.

Read guide